
In 2023, kidney cancers are expected to affect around 81,800 patients, resulting in an estimated 14,890 deaths. Treatment for renal cell carcinoma (RCC) has improved, but metastatic RCC still has a poor prognosis. The ASCO GU Cancers Symposium discussed various aspects of RCC treatment, including active surveillance, oligometastatic RCC treatment, consolidation treatment, and second-line systemic therapy. The treatment of mRCC encompasses a wide variety of experts in different disciplines requiring true multidisciplinary care.
Like
Save
Share